Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives

被引：7
作者：
Almeida-Pinto, Nisia [1 ]
Dschietzig, Thomas Bernd [2 ]
Bras-Silva, Carmen [1 ,3 ]
Adao, Rui [1 ,4 ,5 ]
机构：
[1] Univ Porto, Fac Med, Cardiovasc R&D Ctr UnICRISE, Dept Surg & Physiol, P-4200319 Porto, Portugal
[2] Relaxera GmbH & Co KG, Bensheim, Germany
[3] Univ Porto, Fac Nutr & Food Sci, Porto, Portugal
[4] Univ Complutense Madrid, Sch Med, Dept Pharmacol & Toxicol, Madrid, Spain
[5] CIBER Enfermedades Respiratorias CIBERES, Madrid, Spain
来源：
CLINICAL RESEARCH IN CARDIOLOGY | 2024年 / 113卷 / 08期
关键词：
Relaxin; RXFP1; mimetics; Serelaxin; Cardiovascular diseases; Heart failure; SECONDARY DATA SOURCES; HEART-FAILURE; ECONOMIC-EVALUATION; COST-EFFECTIVENESS; HEALTH; READMISSIONS; OUTCOMES; SOCIETY; DESIGN; BURDEN;
D O I：
10.1007/s00392-023-02305-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The hormone relaxin-2 has emerged as a promising player in regulating the physiology of the cardiovascular system. Through binding to the relaxin family peptide receptor 1 (RXFP1), this hormone elicits multiple physiological responses including vasodilation induction, reduction of inflammation and oxidative stress, and angiogenesis stimulation. The role of relaxin-2, or its recombinant human form known as serelaxin, has been investigated in preclinical and clinical studies as a potential therapy for cardiovascular diseases, especially heart failure, whose current therapy is still unoptimized. However, evidence from past clinical trials has been inconsistent and further research is needed to fully understand the potential applications of relaxin-2. This review provides an overview of serelaxin use in clinical trials and discusses future directions in the development of relaxin-2 mimetics, which may offer new therapeutic options for patients with heart failure.
引用
收藏
页码：1137 / 1150
页数：14
相关论文
共 60 条
  • [1] Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
    Adams, KF
    Fonarow, GC
    Emerman, CL
    LeJemtel, TH
    Costanzo, MR
    Abraham, WT
    Berkowitz, RL
    Galvao, M
    Horton, DP
    [J]. AMERICAN HEART JOURNAL, 2005, 149 (02) : 209 - 216
  • [2] The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy
    Alam, Fariha
    Gaspari, Tracey A.
    Kemp-Harper, Barbara K.
    Low, Edward
    Aw, Aaron
    Ferens, Dorota
    Spizzo, Iresha
    Jefferis, Ann-Maree
    Praveen, Praveen
    Widdop, Robert E.
    Bathgate, Ross A. D.
    Hossain, Mohammed Akhter
    Samuel, Chrishan S.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 160
  • [3] [Anonymous], A study of LY3540378 in participants with worsening chronic heart failure with preserved ejection fraction (HFpEF)
  • [4] Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target
    Bani, Daniele
    [J]. DRUG DISCOVERY TODAY, 2020, 25 (07) : 1239 - 1244
  • [5] Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt/β-catenin signaling pathway
    Chen Feiteng
    Chen Lei
    Li Deng
    Xu Chaoliang
    Xu Zijie
    Shao Yi
    Sha Minglei
    [J]. RENAL FAILURE, 2022, 44 (01) : 513 - 524
  • [6] clinicaltrials, Study of the effect of serelaxin on high-sensitivity cardiac troponin I (Hs-cTnI) release in patients with chronic heart failure (RELAX-Cardio)
  • [7] Maternal vasodilation in pregnancy: the emerging role of relaxin
    Conrad, Kirk P.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2011, 301 (02) : R267 - R275
  • [8] Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial
    Corcoran, David
    Radjenovic, Aleksandra
    Mordi, Ify R.
    Nazir, Sheraz A.
    Wilson, Simon J.
    Hinder, Markus
    Yates, Denise P.
    Machineni, Surendra
    Alcantara, Jose
    Prescott, Margaret F.
    Gugliotta, Barbara
    Pang, Yinuo
    Tzemos, Niko
    Semple, Scott, I
    Newby, David E.
    McCann, Gerry P.
    Squire, Iain
    Berry, Colin
    [J]. CARDIOVASCULAR RESEARCH, 2021, 117 (01) : 320 - 329
  • [9] Mega-trials in heart failure: effects of dilution in examination of new therapies
    Davison, Beth A.
    Takagi, Koji
    Senger, Stefanie
    Koch, Gary
    Metra, Marco
    Kimmoun, Antoine
    Mebazaa, Alexandre
    Voors, Adriaan A.
    Nielsen, Olav W.
    Chioncel, Ovidiu
    Pang, Peter S.
    Greenberg, Barry H.
    Maggioni, Aldo P.
    Cohen-Solal, Alain
    Ertl, Georg
    Sato, Naoki
    Teerlink, John R.
    Filippatos, Gerasimos
    Ponikowski, Piotr
    Gayat, Etienne
    Edwards, Christopher
    Cotter, Gad
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (09) : 1698 - 1707
  • [10] The pregnancy hormone relaxin is a player in human heart failure
    Dschietzig, T
    Richter, C
    Bartsch, C
    Laule, M
    Armbruster, FP
    Baumann, G
    Stangl, K
    [J]. FASEB JOURNAL, 2001, 15 (12) : 2187 - 2195
123456